Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 19/20 | 0.87 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.79 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.79 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.79 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.79 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4157298 | 0.93 | GABRA5 (1.00) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL20778806 | 0.90 | GABRA5 (0.77) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL20778905 | 0.88 | GABRA5 (0.69) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| Basmisanil SCHEMBL2685527 | 0.88 | GABRA5 (1.00) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL536008 | 0.87 | GABRA5 (0.80) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| Basmisanil SCHEMBL15064600 | 0.87 | GABRA5 (0.98) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| Basmisanil SCHEMBL20775357 | 0.86 | GABRA5 (0.89) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| Basmisanil SCHEMBL15064759 | 0.85 | GABRA5 (0.89) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL29323855 | 0.84 | GABRA5 (0.76) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL22149681 | 0.84 | GABRA5 (0.73) | GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396572-A1 | Deuterated Alpha5 subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatment for Depression and Mood Disorders | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-12-15 | — | — | US | disclosed |
| US-20200199119-A1 | Deuterated Alpha5 subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatment for Depression and Mood Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199119-A1 | Deuterated Alpha5 subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatment for Depression and Mood Disorders | GABRA5, GABRA4, GABRA1 | GABRA5 1/4885GABRA1 3/4885GABRG2 15/4885 |
| US-20220396572-A1 | Deuterated Alpha5 subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatment for Depression and Mood Disorders | GABRA5, GABRA4, GABRA1 | GABRA5 1/4885GABRA1 3/4885GABRG2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.